Development of LIX1L target-peptide therapy in gastric cancer
| Project/Area Number |
25460384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIBATA Kiyoshi 浜松医科大学, 光尖端医学教育研究センター, 技術専門員 (80397372)
FUJIE Michio 浜松医科大学, 光尖端医学教育研究センター, 技術補佐員 (90397373)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 分子標的薬 / LIX1L蛋白質 / 胃癌 / miRNA / LIX1L / RNA結合蛋白質 / 癌細胞 / 標的分子 / チロシンキナーゼ阻害 / ペプチド / プロテオーム解析 / シグナル伝達 |
|---|
| Outline of Final Research Achievements |
We identified the LIX1L, which specifically expressed in various cancer cells, as a novel marker for cancer. Its function is unknown in detail. In this study, we revealed that LIX1L promoted cancer cell proliferation both in vitro and in vivo. ROS1 kinase phosphorylates 136th Tyrosin in LIX1L, and LIX1L subsequently induces proliferates cancer cells via binding to various RMA including miRNA. We also found peptide, which specifically inhibited the function of LIX1L, and the peptide inhibited gastric cancer cell proliferation as a decay. Therefore, we revealed that LIX1L was specifically expressed in various cancer cells, and the PY136 peptide, which targeted to LIX1L amino acid sequence including 136th Tyrosin, has a possibility as a new molecular targeted agent for cancer therapy in LIX1L expressed cancer cells.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
[Journal Article] CD44-SLC1A2 fusion transcripts in primary colorectal cancer.2015
Author(s)
Shinmura K, Kato H, Igarashi H, Inoue Y, Nakamura S, Du C, Kurachi K, Nakamura T, Ogawa H, Tanahashi M, Niwa H, Sugimura H.
-
Journal Title
Pathol Oncol Res.
Volume: 21
Issue: 3
Pages: 759-764
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung.2014
Author(s)
Shinmura K, Igarashi H, Kato H, Kawanishi Y, Inoue Y, Nakamura S, Ogawa H, Yamashita T, Kawase A, Funai K, Sugimura H.
-
Journal Title
Dis Markers.
Volume: 2014
Pages: 619273-619273
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] RSPO fusion transcripts in colorectal cancer in Japanese population.2014
Author(s)
Shinmura K, Kahyo T, Kato H, Igarashi H, Matsuura S, Nakamura S, Kurachi K, Nakamura T, Ogawa H, Funai K, Tanahashi M, Niwa H, Sugimura H.
-
Journal Title
Mol Biol Rep.
Volume: 41
Issue: 8
Pages: 5375-5384
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Impaired 8-hydroxyguanine repair activity of MUTYH variant p. Arg109Trp found in a Japanese patient with early-onset colorectal cancer2014
Author(s)
Shinmura, K., Goto, M., Tao, H., Kato, H., Suzuki, R., Nakamura, S., Matsuda, T., Yin, G., Morita, M., Kono, S., Sugimura, H.
-
Journal Title
Oxidative Medicine and Cellular Longevity
Volume: 2014
Pages: 617351-617351
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
